A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus

Maria Grazia Revello, M.D., Tiziana Lazzarotto, Ph.D., Brunella Guerra, M.D., Arsenio Spinillo, M.D., Enrico Ferrazzi, M.D., Alessandra Kustermann, M.D., Secondo Guaschino, M.D., Patrizia Vergani, M.D., Tullia Todros, M.D., Tiziana Frusca, M.D., Alessia Arosa, M.D., Milena Furione, M.D., Vanina Rognoni, M.D., Nicola Rizzo, M.D., Liliana Gabrielli, M.D., Catherine Klersy, M.D., and Giuseppe Gerna, M.D., for the CHIP Study Group*

BACKGROUND
Congenital infection with human cytomegalovirus (CMV) is a major cause of morbidity and mortality. In an uncontrolled study published in 2005, administration of CMV-specific hyperimmune globulin to pregnant women with primary CMV infection significantly reduced the rate of intrauterine transmission, from 40% to 16%.

METHODS
We evaluated the efficacy of hyperimmune globulin in a phase 2, randomized, placebo-controlled, double-blind study. A total of 124 pregnant women with primary CMV infection at 5 to 26 weeks of gestation were randomly assigned within 6 weeks after the presumed onset of infection to receive hyperimmune globulin or placebo every 4 weeks until 36 weeks of gestation or until detection of CMV in amniotic fluid. The primary end point was congenital infection diagnosed at birth or by means of amniocentesis.

RESULTS
A total of 123 women could be evaluated in the efficacy analysis (1 woman in the placebo group withdrew). The rate of congenital infection was 30% (18 fetuses or infants of 61 women) in the hyperimmune globulin group and 44% (27 fetuses or infants of 62 women) in the placebo group (a difference of 14 percentage points; 95% confidence interval, −3 to 31; P = 0.13). There was no significant difference between the two groups or, within each group, between the women who transmitted the virus and those who did not, with respect to levels of virus-specific antibodies, T-cell–mediated immune response, or viral DNA in the blood. The clinical outcome of congenital infection at birth was similar in the two groups. The number of obstetrical adverse events was higher in the hyperimmune globulin group than in the placebo group (13% vs. 2%).

CONCLUSIONS
In this study involving 123 women who could be evaluated, treatment with hyperimmune globulin did not significantly modify the course of primary CMV infection during pregnancy. (Fundied by Agenzia Italiana del Farmaco; CHIP ClinicalTrials.gov number, NCT00881517; EudraCT no. 2008-006560-11.)
EVERY YEAR, APPROXIMATELY 0.6% OF ALL newborns in the United States and the European Union are congenitally infected with human cytomegalovirus (CMV).1,2 Approximately 20% of these infected newborns are symptomatic at birth or will have sequelae such as sensorineural hearing loss, cognitive defects, and motor defects.3 Primary CMV infection that develops in a woman during pregnancy confers the highest risk of congenital infection and disease.4 Identification of pregnant women with primary CMV infection is feasible by means of detection of virus-specific IgM and low IgG avidity. However, the unavailability of a therapeutic intervention of proven efficacy in the case of documented maternal infection has been considered to be a major obstacle to the implementation of routine serologic screening of pregnant women.

In 2005, a nonrandomized study showed that when CMV-specific hyperimmune globulin was administered to pregnant women with primary infection, the rate of mother-to-fetus transmission decreased significantly, from 40% to 16% (P=0.04), and the risk of congenital disease also decreased significantly, from 50% to 3% (P<0.001).5 Other nonrandomized studies have shown a decrease in the number of congenitally infected infants born to mothers who had been treated with hyperimmune globulin or improved outcomes in CMV-infected infants.6-9 We designed the current randomized, controlled clinical trial to verify the previously reported efficacy of CMV-specific hyperimmune globulin in preventing fetal infection.10

METHODS

STUDY OVERSIGHT

The Congenital HCMV Infection Prevention (CHIP) trial was a phase 2, double-blind, placebo-controlled, parallel-group trial. We conducted the trial at 11 centers in Italy. The study, which was supported entirely by Agenzia Italiana del Farmaco in Rome,11 was approved by the ethics committees at each participating center. Participants provided written informed consent before study entry. A contract research organization (Clinical Research Technology, Salerno, Italy) was responsible for the regulatory aspects of the study, verification of source documents, and monitoring of safety.

STUDY END POINTS

The primary end point was the number of infected fetuses or newborns of mothers who received treatment with hyperimmune globulin as compared with the number of infected fetuses or newborns of mothers who received placebo. Secondary end points included CMV DNA level, response to the study drug as assessed by means of an enzyme-linked immunosorbent assay (ELISA) and measurements of neutralizing antibodies, lymphocyte subpopulations, and CMV-specific T-cell response; virologic and immunohistologic findings in placentas; ultrasonographic findings in fetuses; clinical outcomes of congenital CMV infection within the first 2 weeks of life; and safety of CMV-specific hyperimmune globulin. Details of the study design are provided in the protocol and the Supplementary Appendix, both of which are available with the full text of this article at NEJM.org.

PARTICIPANTS

Pregnant women who had a primary infection at 5 to 26 weeks of gestation, with a presumed onset of infection within the previous 6 weeks, were invited to participate in the study. Details regarding the identification of women with recent CMV infection, as well as the eligibility criteria, are provided in the Supplementary Appendix. The virology units of Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo in Pavia, Italy, and Sant’Orsola Malfigni Hospital in Bologna, Italy, served as the reference diagnostic centers for confirmation of primary CMV infection.

RANDOMIZATION

Participants were randomly assigned, in a 1:1 ratio, to receive hyperimmune globulin or placebo. Randomization was performed with the use of a computer-based randomization list that was generated by the study statistician and provided to the study pharmacists by the contract research organization. Randomization, which was performed with the use of Stata software, was balanced in blocks of various sizes, with stratification according to center. Participants, personnel administering the study drugs, physicians, technicians, and the study statistician were unaware of the study-group assignments until completion of the study and retrospective analysis of the samples.
The hyperimmune globulin preparation (purchased from Cytotect, Biotest Pharma, which had no other role in the study) is a ready-for-use solution that contains 50 U of anti–CMV IgG antibody per milliliter (100 mg of protein of plasma origin per milliliter, resulting in ≥95% IgG). The dose was 100 U (2.0 ml) per kilogram of body weight administered intravenously (see the Supplementary Appendix for details and for the lot numbers of the preparations). The placebo was a 0.9% saline solution and was given intravenously at the same dose (2.0 ml per kilogram) as the active drug. Infusion bags containing the required volume of drug or placebo were prepared at each center by the study pharmacist and sealed with aluminum foil. Only the randomization number was written on the label. Pregnant women received hyperimmune globulin or placebo every 4 weeks until 36 weeks of gestation, detection of CMV in the amniotic fluid (in the case of women who underwent amniocentesis), or spontaneous termination of the pregnancy. Before each infusion, blood samples were obtained for retrospective analysis.

**LABORATORY TESTS**

Levels of virus-specific IgG and IgM antibodies were determined with the use of the ETI-CYTOK-G PLUS and ETI-CYTOK-M reverse PLUS ELISAs, respectively (Diasorin), and IgG avidity was determined with the use of the CMV IgG avidity test (Radim). Neutralizing antibodies against the AD169 strain of CMV in human fibroblasts and the VK1814 strain of CMV in epithelial (spontaneously arising retinal pigment epithelial [ARPE]-19) cells were assessed as described previously. Viral DNA in the blood was determined with the use of a real-time polymerase-chain-reaction (PCR) assay (CMV ELITE MGB Kit, ELITechGroup). Positive samples with less than 396 IU per milliliter were assigned an arbitrary value of 200 IU. Antigenemia was determined as described previously. Rapid isolation of the virus from amniotic fluid or urine samples and real-time PCR analysis of those samples were used for the diagnosis of congenital infection. Viral load in placentas was determined retrospectively by means of flow cytometry, as described previously.  

**DIAGNOSIS AND DATING OF PRESUMED ONSET OF MATERNAL INFECTION**

The diagnosis of primary CMV infection was based on seroconversion (i.e., an appearance of virus-specific antibodies in a previously seronegative woman) or the concomitant presence of CMV-specific IgM antibodies and low IgG avidity. The onset of infection was established on the basis of clinical symptoms, when they were present. In the case of asymptomatic seroconversion, onset was arbitrarily set midway between the time of the last seronegative serum sample and the first seropositive serum sample. In addition, one or more of the following findings were considered to be consistent with an onset of infection less than 6 weeks previously: an IgM value that was 10 or more times the cutoff value, IgG avidity of less than 15% (avidity of <35% indicates a primary infection acquired <12 weeks earlier), or detection of pp65 antigenemia.

**STATISTICAL ANALYSIS**

We estimated that we would need to enroll 60 women in each group for the study to have 80% power to confirm the reduction in congenital infection from 40% to 16% reported by Nigro et al., at a 5% type I error rate and assuming a 10% rate of withdrawal. A 36-month enrollment period was anticipated for recruiting this number of patients. The statistical analyses followed the intention-to-treat principle for the efficacy end points and the on-treatment principle for the safety end points. The analysis population consisted of all women who underwent randomization and were assessed for the primary end point. The incidence of the primary end point was compared between the two study groups with the use of Fisher’s exact test, and the difference in risk was calculated together with its 95% confidence interval. We used Fisher’s exact test to compare categorical secondary end points, the Mann–Whitney U test to compare continuous secondary end points, and the log-rank test to compare time-to-event secondary end points. A futility analysis was planned after half the study participants had reached the primary end point, with the aim of recommending the discontinuation of the study if the 95% confidence interval...
for the difference in risk did not include at least a 10-percentage-point benefit with the active drug. All the analyses were performed with the use of Stata 12 software (StataCorp). A two-sided P value of less than 0.05 was considered to indicate statistical significance.

RESULTS

ENROLLMENT

Enrollment took place from June 2009 through March 2011, and the last newborn was examined in November 2011. Of 338 pregnant women who received a diagnosis of primary CMV infection, 181 (54%) were excluded, and 33 of the 157 eligible women (21%) declined to participate in the study (Fig. 1). Of the 124 women enrolled, 123 completed the study and were included in the efficacy analysis. There were no significant differences between the two groups in any of the baseline characteristics, including the method used for determining the onset of infection (Table 1).

In both groups, the diagnosis of primary infection based on testing for seroconversion was made later during pregnancy than was diagnosis based on CMV-specific IgM antibody level and IgG avidity (14 weeks [range, 7 to 26] vs. 8 weeks [range, 5 to 18] in the hyperimmune globulin group and 17 weeks [range, 6 to 26] vs. 8 weeks [range, 6 to 17] in the placebo group). Overall,
Table 1. Baseline Characteristics of the Study Participants.*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hyperimmune Globulin (N = 61)</th>
<th>Placebo (N = 62)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age — yr</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>33</td>
<td>33</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>30–35</td>
<td>29–35</td>
</tr>
<tr>
<td><strong>Parity — no. (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>20 (33)</td>
<td>18 (29)</td>
</tr>
<tr>
<td>≥1</td>
<td>41 (67)</td>
<td>44 (71)</td>
</tr>
<tr>
<td><strong>Evidence of infection — no. (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG seroconversion</td>
<td>44 (72)</td>
<td>44 (71)</td>
</tr>
<tr>
<td>IgM antibodies and low IgG avidity</td>
<td>17 (28)</td>
<td>18 (29)</td>
</tr>
<tr>
<td>Gestation at onset of maternal infection — wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>10–18</td>
<td>8–20</td>
</tr>
<tr>
<td>Interval between onset of infection and treatment — wk</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interquartile range</td>
<td>4–5</td>
<td>4–6</td>
</tr>
<tr>
<td><strong>Presence of symptoms or signs — no. (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38 (62)</td>
<td>34 (55)</td>
<td></td>
</tr>
<tr>
<td><strong>Evidence for dating of presumed onset of infection — no. (%)</strong></td>
<td>24 (39)</td>
<td>16 (26)</td>
</tr>
<tr>
<td>Seroconversion and symptoms or signs, plus IgM ratio ≥10, avidity &lt;15%, or positive for pp65 antigenemia</td>
<td>24 (39)</td>
<td>16 (26)</td>
</tr>
<tr>
<td>Seroconversion without symptoms or signs plus IgM ratio ≥10, avidity &lt;15%, or positive for pp65 antigenemia</td>
<td>11 (18)</td>
<td>17 (27)</td>
</tr>
<tr>
<td>Seroconversion, with or without symptoms or signs</td>
<td>9 (15)</td>
<td>11 (18)</td>
</tr>
<tr>
<td>Avidity &lt;15%, with or without symptoms or signs</td>
<td>10 (16)</td>
<td>12 (19)</td>
</tr>
<tr>
<td>IgM ratio ≥10, with or without symptoms or signs</td>
<td>4 (7)</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Avidity &lt;15% plus IgM ratio ≥10 or pp65 antigenemia, with or without symptoms or signs</td>
<td>3 (5)</td>
<td>3 (5)</td>
</tr>
</tbody>
</table>

* There were no significant differences between the two groups in any of the baseline characteristics.

72 of the 123 women with primary infection (59%) reported symptoms (45 women), had abnormal laboratory findings (13 women, 8 with abnormal liver enzyme levels and 5 with lymphocytosis), or both (14 women with symptoms and abnormal liver enzyme levels) that were compatible with primary CMV infection. Fever, asthenia, and an influenza-like syndrome, together with abnormal liver enzyme levels, were the symptoms and signs reported most frequently.

INFUSIONS

A total of 271 infusions were administered in the hyperimmune globulin group, and 254 in the placebo group. The median number of infusions received by each woman did not differ significantly between the hyperimmune globulin group and the placebo group (5 infusions [interquartile range, 3 to 6] and 4 infusions [interquartile range, 3 to 6], respectively; P = 0.60).

**PRIMARY END POINT**

Intrauterine transmission occurred in 45 of 123 cases (37%). Congenital infection was diagnosed before birth in 18 fetuses and at birth in 27 newborns. Three of the 40 newborns (8%) who had tested negative for CMV when amniocentesis was performed were found at birth to be infected (Fig. 2). A total of 18 congenital infections occurred among the fetuses or newborns of the 61
women in the hyperimmune globulin group (30%), and 27 among the fetuses or newborns of the 62 women in the placebo group (44%), for a difference of 14 percentage points (95% confidence interval, −3 to 31; P = 0.13). Of the 18 women in the hyperimmune globulin group who transmitted the virus, 9 of the mothers received a diagnosis of CMV during the first trimester and 9 during the second trimester; of the 27 women in the placebo group who transmitted the virus, 12 received a diagnosis of CMV during the first trimester and 15 during the second trimester. A nonsignificant difference in the transmission rate was observed when only fetuses or only newborns were included in the analysis and when only mothers who underwent seroconversion were included. No significant difference between the two groups was observed with respect to the viral DNA load in the amniotic fluid of infected fetuses or with respect to levels of viral DNA in urine or blood or virus-specific IgM in infected newborns (Table 2).

**IMMUNOLOGIC AND VIROLOGIC ANALYSES OF MATERNAL BLOOD**

No significant difference was observed between the two groups with respect to CMV-specific IgG and IgM, IgG avidity, or levels of neutralizing antibodies (as determined in human fibroblasts and ARPE-19 epithelial cells) (Table S1 in the
Supplementary Appendix). At the time of enrollment, all the women were already positive for VR1814-neutralizing antibodies (in epithelial cells), whereas AD169-neutralizing antibodies (in fibroblast cells) were not detected in 18 of 59 women (31%) in the hyperimmune globulin group or in 20 of 62 women (32%) in the placebo group. At study end, all the women in both groups were positive for AD169 neutralizing antibodies. The findings with respect to lymphocyte subpopulations, CMV-specific cell-mediated immunity, and level of CMV DNA in the blood were similar in the two groups (Table S1 in the Supplementary Appendix), as was the time to clearance of viral DNA from the blood (Fig. S1 in the Supplementary Appendix).

When the characteristics of women who transmitted the virus and those of women who did not transmit the virus were compared between the two study groups and within each study group, no significant difference was observed with respect to the week of gestation at the onset of infection, the number of weeks between the diagnosis of infection and treatment (Table S2 in the Supplementary Appendix), or any of the other immunologic or virologic variables investigated (Table S3 in the Supplementary Appendix).

ADVERSE EVENTS

A total of 20 adverse events were reported in 16 women, including 11 serious adverse events in 10 women. The serious adverse events in the hyperimmune globulin group were preterm delivery (4 women, at 25, 32, 33, and 33 weeks), intrauterine growth restriction and induction of preterm delivery (1 woman, at 36 weeks), intrauterine growth restriction (1 woman), and intrahepatic cholestasis of pregnancy and postpartum eclampsia (2 events in 1 woman). The serious adverse events in the placebo group were spontaneous abortion after amniocentesis, arthralgia of the upper and lower limbs, and pregnancy-induced hypertension (1 woman each). Adverse events in the hyperimmune globulin group included pruritus of the lower limbs (3 events in 1 woman), headache (1 woman), and vomiting (1 woman). Adverse events in the placebo group included asthenia (1 woman), headache (1 woman), and thrombocytopenia (2 events in 1 woman). Overall, obstetrical complications (preterm delivery, preeclampsia, and fetal growth restriction) were recorded in 7 of 53 women (13%) in the hyperimmune globulin group who remained in the study until the time of delivery, as compared with 1 of 51 women (2%) in the placebo group (P=0.06).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mothers Received Hyperimmune Globulin</th>
<th>Mothers Received Placebo</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetuses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. with infection</td>
<td>8</td>
<td>10</td>
<td>0.40</td>
</tr>
<tr>
<td>Viral DNA in amniotic fluid — log_{10} copies/ml</td>
<td>6.8</td>
<td>6.6</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td>5.20–7.48</td>
<td>6.14–7.09</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>5.20–7.48</td>
<td>6.14–7.09</td>
<td></td>
</tr>
<tr>
<td>Newborns</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. with infection</td>
<td>10</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Positive for viral DNA in blood — no. (%)</td>
<td>10 (100)</td>
<td>15 (88)</td>
<td>0.51</td>
</tr>
<tr>
<td>Viral DNA in blood — IU/ml</td>
<td>1353</td>
<td>925</td>
<td>0.38</td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td>200–13,457</td>
<td>200–2061</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>200–13,457</td>
<td>200–2061</td>
<td></td>
</tr>
<tr>
<td>Viral DNA in urine — log_{10} copies/ml</td>
<td>7.39</td>
<td>7.11</td>
<td>1.00</td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td>5.91–7.85</td>
<td>6.67–7.62</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>5.91–7.85</td>
<td>6.67–7.62</td>
<td></td>
</tr>
<tr>
<td>Positive for IgM — no./total no. tested (%)</td>
<td>4/9 (44)</td>
<td>4/16 (25)</td>
<td>0.39</td>
</tr>
</tbody>
</table>
CLINICAL OUTCOME IN NEWBORNS

Overall, 104 women remained in the study until the time of delivery (Fig. 2). No significant differences with respect to sex, weight, gestational age at birth, or Apgar score were observed between newborns whose mothers had received hyperimmune globulin and newborns whose mothers had received placebo. The most frequent complication among babies born to mothers who had received hyperimmune globulin was prematurity (Table 3). Premature birth was recorded in 7 of 48 babies (15%) born to mothers who had received hyperimmune globulin and in 1 of 47 babies (2%) born to mothers who had received placebo (P=0.06). Six of the 7 premature babies born to mothers who had received hyperimmune globulin were not infected with CMV. Three infants born to mothers in the hyperimmune globulin group had a low birth weight (range, 1880 to 2170 g), and 1 infant had an extremely low birth weight (870 g). Three of 10 CMV-infected newborns in the hyperimmune globulin group (30%) and 4 of 17 in the placebo group (24%) had symptoms at birth.

OTHER SECONDARY END POINTS

Preliminary analysis of fetal records indicated that there were no significant differences between the two study groups in ultrasonographic findings: 7 of 61 fetuses (11%) in the hyperimmune globulin group and 10 of 62 (16%) in the placebo group had transient or permanent abnormalities. Similarly, the median DNA viral load in 19 term placentas (10 from mothers in the hyperimmune globulin group and 9 from mothers in the placebo group) did not differ significantly between the two groups and was low in both groups (10 copies per 0.005 μg [range, 10 to 10] and 16 copies per 0.005 μg [range, 10 to 34], respectively).

DISCUSSION

This controlled study did not show a significant reduction in the rate of transmission of CMV infection among women receiving hyperimmune globulin as compared with women receiving placebo. Moreover, this study showed no effect of hyperimmune globulin on the activity of neutral-
ning antibodies. Previous data showed that neutralizing antibodies, as measured in endothelial or epithelial cells with the use of the VR1814 CMV prototype, are directed primarily against the pentameric gH/gL/pUL128L complex and represent the major neutralizing component of human serum and commercial hyperimmune globulin.\textsuperscript{19,20} As confirmed in this study, these neutralizing antibodies are produced and peak very early after the onset of primary infection, without a clear difference between mothers who transmit the virus and mothers who do not.\textsuperscript{12,21}

On the other hand, neutralizing antibodies against AD169 are slower to develop,\textsuperscript{12,21,22} and in our study, administration of hyperimmune globulin did not significantly modify their levels.

Similarly, hyperimmune globulin did not significantly modify maternal levels of DNA in the blood or the time to clearance of DNA from the blood, nor did it significantly modify DNA levels in placentas. No significant differences in the level of DNA in the blood were noted in either study group between women who transmitted the virus and those who did not — a finding that was in agreement with results of a previous study.\textsuperscript{23} These findings do not support the explanation that hyperimmune globulin could act by reducing the maternal or placental viral load through a direct neutralization effect, as hypothesized by Nigro and colleagues.\textsuperscript{5} Finally, administration of hyperimmune globulin apparently had no effect on the virus-specific T-cell responses.

One challenging aspect of the CHIP study was establishing the presumed onset of primary infection. Relying on the experience of the two reference diagnostic centers, in Pavia and Bologna, we defined the onset of primary infection as the reported date of the onset of symptoms or signs when those reports were in agreement with serologic results. In this study, symptoms and signs were reported by about 60% of the women. Other studies have shown similar rates.\textsuperscript{20-28} In addition, on the basis of our experience with the assays used in this study, when the results of serologic tests reached pre-specified levels (i.e., an IgM ratio higher than 10 times the cutoff value or IgG avidity lower than 15%), the onset was assumed to have occurred during the previous 6 weeks. CMV antigenemia was another criterion, since its detection is restricted to the early phase of primary infection in immunocompetent persons.\textsuperscript{29} Altogether, the above criteria were considered to be strict enough to reasonably exclude infections acquired earlier than 6 weeks before enrollment.

Another critical point was that we excluded from our analysis infections that occurred before conception, since the risk of fetal infection associated with maternal infection acquired before pregnancy is lower than that reported after primary infection during the first trimester of gestation (approximately 5% vs. approximately 40%).\textsuperscript{24,30,31} We excluded those infections by restricting the enrollment to women with primary infection acquired after the fifth week of pregnancy. In the study by Nigro et al.,\textsuperscript{5} the median week of gestation at the time of maternal infection was significantly earlier in the group of women who received prophylactic hyperimmune globulin treatment than in the group of women who did not receive hyperimmune globulin (14 weeks vs. 20 weeks) (P<0.01), and the rate of transmission was significantly lower among the pretreated women as well.

In this study three cases of false negative prenatal diagnosis were observed in the hyperimmune globulin group. False negative results have been reported previously.\textsuperscript{32,33}

A recent preliminary evaluation of the safety and efficacy of standard preparations of intravenous immune globulin in pregnant women with primary CMV infection showed an increase in CMV IgG titers and avidity.\textsuperscript{34} In that study, 27 of 67 newborns (40%) born to mothers who had been treated with intravenous immune globulin were found to be infected at birth. However, it is not clear whether the lower preventive efficacy of standard immune globulin as compared with hyperimmune globulin is due to differences between study protocols or immune globulin preparations.\textsuperscript{35}

Finally, a higher number of serious adverse events were recorded among women who received hyperimmune globulin and among their newborns than among women who received placebo and their newborns. The administration of intravenous immune globulin can have adverse effects. Fortunately, most adverse events have been mild.\textsuperscript{36} Although the higher rate of preterm deliveries observed among women in the hyperimmune globulin group raises some concerns, at the moment there is no definitive indication that preterm birth is a hyperimmune globulin–related adverse event.
From the cost-effectiveness point of view, our results (a 32% relative decrease in the transmission rate and no significant difference in the clinical outcome at birth) represent less than the 47% reduction in congenital CMV that has been considered by some to be the threshold for recommending screening for and treatment of primary maternal infection in pregnancy as a cost-effective strategy.37

Currently, two randomized, phase 3 studies of the prevention of congenital infection are under way. One, sponsored by Biotest, is being conducted in Europe,38 and the second, sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is ongoing in the United States (ClinicalTrials.gov number, NCT01376778). The hope is that the results of these studies will further our understanding of the efficacy and safety of hyperimmune globulin administration as a means of preventing congenital CMV infection.

In conclusion, this randomized, placebo-controlled trial of virus-specific hyperimmune globulin for the prevention of congenital CMV infection showed no significant between-group difference in either the primary outcome or the secondary clinical and biologic outcomes examined. However, because the effect was smaller than expected, the power to detect such a difference was small (33%). About three times as many patients would have had to have been enrolled for the study to have had the power to detect a 14-percentage-point difference in the primary outcome.

Supported by a grant (FARM7J4HCH) from Agenzia Italiana del Farmaco.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank all the women who participated in the trial, the pharmacists and nurses who made the study possible, Elena Percivalle and Chiara Fornara from Fondazione IRCCS Policlinico San Matteo of Pavia for their technical expertise, and Daniela Sartori and Laurene Kelly for assistance with the preparation of the manuscript.

This article is dedicated to the memory of Umberto Nicolini, who made a major contribution to the study of CMV infection in pregnancy and who died soon after the design of this study had been completed.

APPENDIX

The authors’ affiliations are as follows: the Departments of Obstetrics and Gynecology (M.G.R., A.S., A.A.), Virology Unit (M.F.), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is ongoing in the United States (ClinicalTrials.gov number, NCT01376778). The hope is that the results of these studies will further our understanding of the efficacy and safety of hyperimmune globulin administration as a means of preventing congenital CMV infection.

In conclusion, this randomized, placebo-controlled trial of virus-specific hyperimmune globulin for the prevention of congenital CMV infection showed no significant between-group difference in either the primary outcome or the secondary clinical and biologic outcomes examined. However, because the effect was smaller than expected, the power to detect such a difference was small (33%). About three times as many patients would have had to have been enrolled for the study to have had the power to detect a 14-percentage-point difference in the primary outcome.

Supported by a grant (FARM7J4HCH) from Agenzia Italiana del Farmaco.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank all the women who participated in the trial, the pharmacists and nurses who made the study possible, Elena Percivalle and Chiara Fornara from Fondazione IRCCS Policlinico San Matteo of Pavia for their technical expertise, and Daniela Sartori and Laurene Kelly for assistance with the preparation of the manuscript.

This article is dedicated to the memory of Umberto Nicolini, who made a major contribution to the study of CMV infection in pregnancy and who died soon after the design of this study had been completed.

REFERENCES


Copyright © 2014 Massachusetts Medical Society.